For all gastric cancer cases, our results showed that high ERBB2 expression was associated with the worse overall survival of GC patients, VIM, IFI44, IFIT2, and MX1 showed similar associations (P < 0.05) (Figures 3(a) and 3(c) and Table 3). Here, ERBB2 is linked to gastric cancer.